• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

利用日本电子病历大数据调查利奈唑胺诱导血小板减少症的危险因素及其高危组合。

Use of Japanese big data from electronic medical records to investigate risk factors and identify their high-risk combinations for linezolid-induced thrombocytopenia.

机构信息

Graduate School of Life Science, Hokkaido University, Kita 10-Jo, Nishi 8-Chome, Kita-Ku, Sapporo, 060-0810, Japan.

Department of Pharmacy, Hokkaido University Hospital, Kita 14-Jo, Nishi 5-Chome, Kita-Ku, Sapporo, 060-8648, Japan.

出版信息

Eur J Clin Pharmacol. 2023 Mar;79(3):415-425. doi: 10.1007/s00228-023-03455-x. Epub 2023 Jan 30.

DOI:10.1007/s00228-023-03455-x
PMID:36715711
Abstract

PURPOSE

Thrombocytopenia is a major event associated with linezolid (LZD) therapy. Factors affecting LZD-induced thrombocytopenia (LIT) have been reported in previous studies. However, several issues pertaining to LIT have not yet been clarified. In the present study, we used Japanese big data to investigate associated factors and their high-risk combinations that influence LIT.

METHODS

Patients administered LZD between May 2006 and October 2020 were included in this study. LIT was defined as either a 30% or more reduction from the baseline platelets or platelet values of < 100,000/µL. We evaluated factors affecting LIT and combinations of factors that alter LIT risk according to a decision tree (DT) analysis, a typical machine learning method.

RESULTS

We successfully enrolled 1399 patients and LIT occurred in 44.7% of the patients (n = 626). We classified the laboratory data on renal function, LZD duration, age, and body weight (BW) into smaller categories. The results of multivariate analysis showed that prolonged LZD therapy, BW < 45 kg, estimated glomerular filtration rate (eGFR) < 30 mL/min/1.73 m, and dialysis were risk factors for LIT. The DT analysis revealed that the highest risk was a combination of LZD duration ≥ 14 days and eGFR < 30 mL/min/1.73 m.

CONCLUSIONS

The present study extracted four risk factors and identified high-risk combinations for LIT. Patients with these risk factors should be closely monitored.

摘要

目的

血小板减少症是与利奈唑胺(LZD)治疗相关的主要事件。先前的研究已经报道了影响 LZD 诱导的血小板减少症(LIT)的因素。然而,关于 LIT 的几个问题尚未得到澄清。在本研究中,我们使用日本大数据调查了影响 LIT 的相关因素及其高危组合。

方法

本研究纳入了 2006 年 5 月至 2020 年 10 月期间接受 LZD 治疗的患者。LIT 定义为基线血小板减少 30%或以上,或血小板值<100,000/μL。我们根据决策树(DT)分析评估了影响 LIT 的因素以及改变 LIT 风险的因素组合,这是一种典型的机器学习方法。

结果

我们成功纳入了 1399 例患者,其中 44.7%(n=626)发生了 LIT。我们将肾功能、LZD 持续时间、年龄和体重(BW)的实验室数据分为更小的类别。多变量分析结果表明,LZD 治疗时间延长、BW<45kg、估计肾小球滤过率(eGFR)<30mL/min/1.73m 和透析是 LIT 的危险因素。DT 分析显示,LZD 持续时间≥14 天和 eGFR<30mL/min/1.73m 的组合风险最高。

结论

本研究提取了四个 LIT 的危险因素,并确定了高危组合。具有这些危险因素的患者应密切监测。

相似文献

1
Use of Japanese big data from electronic medical records to investigate risk factors and identify their high-risk combinations for linezolid-induced thrombocytopenia.利用日本电子病历大数据调查利奈唑胺诱导血小板减少症的危险因素及其高危组合。
Eur J Clin Pharmacol. 2023 Mar;79(3):415-425. doi: 10.1007/s00228-023-03455-x. Epub 2023 Jan 30.
2
Pharmacokinetic and pharmacodynamic simulation for the quantitative risk assessment of linezolid-associated thrombocytopenia.基于药代动力学和药效学模拟的利奈唑胺相关性血小板减少症定量风险评估。
J Clin Pharm Ther. 2022 Dec;47(12):2041-2048. doi: 10.1111/jcpt.13747. Epub 2022 Jul 27.
3
Risk factors for thrombocytopenia in patients receiving linezolid therapy: a systematic review and meta-analysis.利奈唑胺治疗患者血小板减少症的危险因素:系统评价和荟萃分析。
Eur J Clin Pharmacol. 2023 Oct;79(10):1303-1314. doi: 10.1007/s00228-023-03542-z. Epub 2023 Aug 14.
4
Analysis of the risk factors of linezolid-related haematological toxicity in Chinese patients.分析利奈唑胺相关血液毒性的中国患者的危险因素。
J Clin Pharm Ther. 2021 Jun;46(3):807-813. doi: 10.1111/jcpt.13359. Epub 2021 Feb 8.
5
Association of clinical factors with thrombocytopenia in patients receiving linezolid treatment: a retrospective study.接受利奈唑胺治疗患者的临床因素与血小板减少症的相关性:一项回顾性研究。
J Infect Dev Ctries. 2024 Feb 29;18(2):285-290. doi: 10.3855/jidc.18488.
6
A retrospective study of the risk factors for linezolid-induced thrombocytopenia and anemia.一项关于利奈唑胺诱导的血小板减少症和贫血危险因素的回顾性研究。
J Infect Chemother. 2016 Aug;22(8):536-42. doi: 10.1016/j.jiac.2016.05.003. Epub 2016 Jun 16.
7
The association between risk factors and time of onset for thrombocytopenia in Japanese patients receiving linezolid therapy: a retrospective analysis.日本接受利奈唑胺治疗患者血小板减少症的危险因素与发病时间的关联:一项回顾性分析。
J Clin Pharm Ther. 2015 Jun;40(3):279-84. doi: 10.1111/jcpt.12260. Epub 2015 Mar 2.
8
Number of concomitant drugs with thrombocytopenic adverse effects and the extent inflammatory response resolution are risk factors for thrombocytopenia in patients treated with linezolid for more than 14 days.接受利奈唑胺治疗超过14天的患者中,具有血小板减少不良反应的伴随用药数量以及炎症反应消退程度是血小板减少的危险因素。
Nagoya J Med Sci. 2020 Aug;82(3):407-414. doi: 10.18999/nagjms.82.3.407.
9
A Regression Model to Predict Linezolid Induced Thrombocytopenia in Neonatal Sepsis Patients: A Ten-Year Retrospective Cohort Study.预测新生儿败血症患者利奈唑胺诱导血小板减少症的回归模型:一项十年回顾性队列研究。
Front Pharmacol. 2022 Feb 3;13:710099. doi: 10.3389/fphar.2022.710099. eCollection 2022.
10
Therapeutic drug monitoring of linezolid and exploring optimal regimens and a toxicity-related nomogram in elderly patients: a multicentre, prospective, non-interventional study.利奈唑胺的治疗药物监测及探索老年患者的最佳方案和与毒性相关的列线图:一项多中心、前瞻性、非干预性研究。
J Antimicrob Chemother. 2024 Aug 1;79(8):1938-1950. doi: 10.1093/jac/dkae188.

引用本文的文献

1
Comparative analysis of thrombocytopenia incidence in patients treated with generic vs. brand-name linezolid: a cohort study utilizing hospital electronic medical records.使用通用型与品牌型利奈唑胺治疗的患者血小板减少症发生率的比较分析:一项利用医院电子病历的队列研究。
Front Pharmacol. 2025 Jun 18;16:1528633. doi: 10.3389/fphar.2025.1528633. eCollection 2025.
2
Exploring the impact of baseline platelet count on linezolid-induced thrombocytopenia: a retrospective single-center observation study.探索基线血小板计数对利奈唑胺所致血小板减少症的影响:一项回顾性单中心观察研究。
Int J Clin Pharm. 2025 Feb;47(1):90-98. doi: 10.1007/s11096-024-01810-1. Epub 2024 Oct 4.
3

本文引用的文献

1
Using Japanese big data to investigate novel factors and their high-risk combinations that affect vancomycin-induced nephrotoxicity.利用日本大数据研究影响万古霉素诱导性肾毒性的新因素及其高危组合。
Br J Clin Pharmacol. 2022 Jul;88(7):3241-3255. doi: 10.1111/bcp.15252. Epub 2022 Feb 17.
2
Clinical Use and Adverse Drug Reactions of Linezolid: A Retrospective Study in Four Belgian Hospital Centers.利奈唑胺的临床应用及药物不良反应:比利时四个医院中心的回顾性研究
Antibiotics (Basel). 2021 May 4;10(5):530. doi: 10.3390/antibiotics10050530.
3
Proposal of initial and maintenance dosing regimens with linezolid for renal impairment patients.
Development and validation of a risk prediction model for linezolid-induced anemia in elderly patients: a retrospective cohort study.
老年患者利奈唑胺所致贫血风险预测模型的建立与验证:一项回顾性队列研究
Ther Adv Drug Saf. 2024 Sep 23;15:20420986241279128. doi: 10.1177/20420986241279128. eCollection 2024.
4
Retrospective Analysis of Risk Factors for Cefoperazone/Sulbactam-Induced Thrombocytopenia in Adult Chinese Patients: A Six-Year Real-World Study.中国成年患者头孢哌酮/舒巴坦致血小板减少症危险因素的回顾性分析:一项为期六年的真实世界研究
Infect Drug Resist. 2024 Sep 5;17:3901-3911. doi: 10.2147/IDR.S475590. eCollection 2024.
5
Towards a better detection of patients at-risk of linezolid toxicity in clinical practice: a prospective study in three Belgian hospital centers.迈向在临床实践中更好地检测有接受利奈唑胺治疗毒性风险的患者:一项在比利时三个医院中心开展的前瞻性研究。
Front Pharmacol. 2024 Jan 19;15:1310309. doi: 10.3389/fphar.2024.1310309. eCollection 2024.
6
Monitoring Salivary Concentrations of Tedizolid and Linezolid Using Rats.监测使用大鼠的替加环素和利奈唑胺的唾液浓度。
Eur J Drug Metab Pharmacokinet. 2023 Jul;48(4):387-395. doi: 10.1007/s13318-023-00836-6. Epub 2023 Jun 27.
利奈唑胺在肾功能损害患者中的初始和维持剂量方案的建议。
BMC Pharmacol Toxicol. 2021 Mar 4;22(1):13. doi: 10.1186/s40360-021-00479-w.
4
Analysis of the risk factors of linezolid-related haematological toxicity in Chinese patients.分析利奈唑胺相关血液毒性的中国患者的危险因素。
J Clin Pharm Ther. 2021 Jun;46(3):807-813. doi: 10.1111/jcpt.13359. Epub 2021 Feb 8.
5
A Risk Prediction Flowchart of Vancomycin-Induced Acute Kidney Injury to Use When Starting Vancomycin Administration: A Multicenter Retrospective Study.万古霉素给药开始时使用的万古霉素诱导急性肾损伤风险预测流程图:一项多中心回顾性研究
Antibiotics (Basel). 2020 Dec 18;9(12):920. doi: 10.3390/antibiotics9120920.
6
Reappraisal of Linezolid Dosing in Renal Impairment To Improve Safety.重新评估肾功能损害患者中利奈唑胺的剂量以提高安全性。
Antimicrob Agents Chemother. 2019 Jul 25;63(8). doi: 10.1128/AAC.00605-19. Print 2019 Aug.
7
Risk factors for linezolid-induced thrombocytopenia in patients without haemato-oncologic diseases.无血液肿瘤疾病患者应用利奈唑胺致血小板减少的危险因素。
Basic Clin Pharmacol Toxicol. 2019 Feb;124(2):228-234. doi: 10.1111/bcpt.13123. Epub 2018 Oct 9.
8
Usefulness of a decision tree model for the analysis of adverse drug reactions: Evaluation of a risk prediction model of vancomycin-associated nephrotoxicity constructed using a data mining procedure.决策树模型在药物不良反应分析中的应用:对采用数据挖掘程序构建的万古霉素相关性肾毒性风险预测模型的评估。
J Eval Clin Pract. 2017 Dec;23(6):1240-1246. doi: 10.1111/jep.12767. Epub 2017 May 23.
9
A 10-Year Experience of Therapeutic Drug Monitoring (TDM) of Linezolid in a Hospital-wide Population of Patients Receiving Conventional Dosing: Is there Enough Evidence for Suggesting TDM in the Majority of Patients?利奈唑胺在全院接受常规剂量治疗患者中的治疗药物监测(TDM)10年经验:是否有足够证据建议对大多数患者进行TDM?
Basic Clin Pharmacol Toxicol. 2017 Oct;121(4):303-308. doi: 10.1111/bcpt.12797. Epub 2017 Jun 19.
10
Linezolid-Induced Thrombocytopenia Is Caused by Suppression of Platelet Production via Phosphorylation of Myosin Light Chain 2.利奈唑胺诱导的血小板减少是由肌球蛋白轻链2磷酸化抑制血小板生成所致。
Biol Pharm Bull. 2016;39(11):1846-1851. doi: 10.1248/bpb.b16-00427.